Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
RAY-121 by Chugai Pharmaceutical for Immune Mediated Necrotizing Myopathy (IMNM): Likelihood of Approval
RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Immune Mediated Necrotizing Myopathy (IMNM). According...
RAY-121 by Chugai Pharmaceutical for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....
RAY-121 by Chugai Pharmaceutical for Dermatomyositis: Likelihood of Approval
RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Dermatomyositis. According to GlobalData, Phase I...
RAY-121 by Chugai Pharmaceutical for Antiphospholipid Syndrome: Likelihood of Approval
RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Antiphospholipid Syndrome. According to GlobalData, Phase...
RAY-121 by Chugai Pharmaceutical for Behcet Disease: Likelihood of Approval
RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Behcet Disease. According to GlobalData, Phase...
RAY-121 by Chugai Pharmaceutical for Bullous Pemphigoid: Likelihood of Approval
RAY-121 is under clinical development by Chugai Pharmaceutical and currently in Phase I for Bullous Pemphigoid. According to GlobalData, Phase...